Chadi hosts Dr. Neal Shore, a urologic oncologist who became heavily involved in GU oncology research – including trials that incorporate systemic chemotherapy. Dr. Shore has a unique practice where he and his staff deliver chemotherapy when appropriate. Chadi was intrigued by this setting as medical oncologists are the ones customarily delivering chemotherapy, and invited him to the show to share how this all started, its pros and cons, and the impact on patients.
Dr. Shore explains how the field has seen drastic changes since the early 1990’s, why he decided to spearhead bringing clinical research into his community clinic, and how his clinic is staffed and structured to support a functioning and successful research hub. Then, the discussion pivots to his recently published clinical trial, ENACT, and the controversy surrounding use of enzalutamide monotherapy in low- or intermediate-risk prostate cancer. There’s been so much controversy and backlash about the ENACT trial that Chadi had to ask him about it and his reaction to what happened when the article was published.
Dr. Joe Mikhael, Chief Medical Officer of the International Myeloma Foundation (IMF) and Professor at TGen, takes us beyond his medical career to explore the personal experiences that have shaped his journey in oncology. Dr. Mikhael discusses the IMF’s targeted strategies for reducing health disparities among diverse ethnic and racial groups affected by myeloma, shedding
Tom Beer, Chief Medical Officer of the Multi-Cancer Early Detection (MCED) program at Exact Sciences, delves into the groundbreaking science behind MCED tests, which use advanced biomarkers for early detection of multiple cancer types. On this Healthcare Unfiltered episode, he explains who may be eligible for these tests, how to interpret results to avoid unnecessary
In this special episode, I give up the microphone to guest host Kelly Ryerson, who takes over the show asking questions about my new book “The Cancer Journey.”
